secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001517022-23-000027
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia delays Form 10-Q filing due to accounting errors; reaffirms 2023 revenue guidance
--------------------------------------------------------------------------------

- Identified accounting errors in recording Auryxia return reserves, delaying Q2 2023 Form 10-Q filing.
- Reaffirms 2023 Auryxia net product revenue guidance of $175-$180 million.
- Cash as of June 30, 2023 plus Auryxia revenues expected to fund operations through at least next twelve months.
- Expects to resubmit NDA for vadadustat for anemia due to CKD in dialysis patients by end of Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000027/0001517022-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000027/akba-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer